Benzinga | Jan 25, 2021 10:18AM EST

Ladenburg Thalmann Initiates Coverage On Plus Therapeutics with Buy Rating, Announces Price Target of $8

Ladenburg Thalmann analyst Robert LeBoyer initiates coverage on Plus Therapeutics (NASDAQ:PSTV) with a Buy rating and announces Price Target of $8.